{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:43:15Z","timestamp":1767706995905,"version":"3.41.2"},"reference-count":25,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T00:00:00Z","timestamp":1743552000000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer Reports"],"published-print":{"date-parts":[[2025,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>The treatment landscape for multiple myeloma continues to evolve. Recently, the addition of anti\u2010CD38 monoclonal antibodies (mAbs) to the triplet regimen, comprising a proteasome inhibitor, an immunomodulatory agent, and a steroid, for transplant\u2010eligible newly diagnosed multiple myeloma (TENDMM) has shown promising results.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aims<\/jats:title><jats:p>To evaluate the overall efficacy and safety of quadruplet therapy with an anti\u2010CD38 mAb compared to a triplet regimen.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A systematic search of Medline, Scopus, and EMBASE databases from inception to July 2024 identified relevant randomized controlled trials (RCTs). Efficacy and safety outcomes were derived using random\u2010effects meta\u2010analysis. Summarized outcomes include hazard ratios (HR) for progression\u2010free survival (PFS) and overall survival (OS), odds ratios (OR) for response rates, measurable residual disease (MRD) negativity rate, and grade 3 or higher adverse events (G\u2009\u2265\u20093 AEs).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Five RCTs involving 2963 patients were included. A statistically significant PFS was observed for quadruplet therapy when compared to the triplet regimen (HR 0.44; 95% Confidence Interval [CI] 0.35\u20130.56). PFS benefit was consistent for the standard risk (SR) group (HR 0.38; 95% CI 0.27\u20130.52) and high risk (HiR) group (HR 0.62; 95% CI 0.41\u20130.92). No statistically significant benefit was observed for OS (HR 0.55; 95% CI 0.28\u20131.08). A statistically significant benefit was observed for the overall response rate (OR 1.77; 95% CI 1.02\u20133.06) and MRD negativity rate (OR 2.67; 95% CI 1.79\u20133.99). No significant differences were observed for G\u2009\u2265\u20093 AE (OR 1.21; 95% CI 0.92\u20131.58), lymphopenia (OR 1.09; 95% CI 0.62\u20131.89), and anemia (OR 1.06; 95% CI 0.83\u20131.37). However, a significantly increased risk was observed for all\u2010grade thrombocytopenia (OR 1.64; 95% CI 1.37\u20131.97), neutropenia (OR 2.24; 95% CI 1.67\u20133.02) and infections (OR 1.88; 95% CI 1.07\u20133.31).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Quadruplet therapy demonstrated a favorable efficacy and safety profile, with consistent benefit across subgroups. The findings support its potential as the new standard of care for TENDMM.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cnr2.70171","type":"journal-article","created":{"date-parts":[[2025,4,7]],"date-time":"2025-04-07T05:41:12Z","timestamp":1744004472000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and Safety of Quadruplet Therapy in Newly Diagnosed Transplant\u2010Eligible Multiple Myeloma: A Systematic Review and Meta\u2010Analysis"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2698-0946","authenticated-orcid":false,"given":"Aneeta","family":"Channar","sequence":"first","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Syed Arsalan Ahmed","family":"Naqvi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad Ali","family":"Khan","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arifa","family":"Bibi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akshat","family":"Saxena","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikita","family":"Tripathi","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmad","family":"Iftikhar","sequence":"additional","affiliation":[{"name":"The University of Arizona  Tucson Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammad","family":"Raina","sequence":"additional","affiliation":[{"name":"Canyon Vista Medical Center  Sierra Vista Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaneez Zahra Rubab","family":"Khakwani","sequence":"additional","affiliation":[{"name":"The University of Arizona  Tucson Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irbaz Bin","family":"Riaz","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology Mayo Clinic  Phoenix Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhammad","family":"Husnain","sequence":"additional","affiliation":[{"name":"The University of Arizona  Tucson Arizona USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,4,2]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(14)70442\u20105"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21654"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2016.11.004"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2011.196"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26590"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102011\u201011\u2010395749"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beha.2020.101143"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/s0140\u20106736(19)31240\u20101"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020005288"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312054"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(22)00263\u20100"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010177546"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2016.3160"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103211"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.4338"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-01440-x"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13317"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/s2352\u20103026(23)00217\u2010x"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-024-01088-6"},{"key":"e_1_2_11_23_1","first-page":"291","volume-title":"How to Treat High\u2010Risk Myeloma at Diagnosis and Relapse","author":"Caro J.","year":"2021"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024371"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood\u20102023\u2010187339"},{"key":"e_1_2_11_26_1","unstructured":"Network NCC \u201cMultiple Myeloma (Version 2.2024) \u201daccessed February 28 2024 https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/myeloma.pdf."}],"container-title":["Cancer Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cnr2.70171","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:06:57Z","timestamp":1745924817000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/cnr2.70171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":25,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10.1002\/cnr2.70171"],"URL":"https:\/\/doi.org\/10.1002\/cnr2.70171","archive":["Portico"],"relation":{},"ISSN":["2573-8348","2573-8348"],"issn-type":[{"type":"print","value":"2573-8348"},{"type":"electronic","value":"2573-8348"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70171"}}